Genelux (GNLX) Shares Outstanding (2022 - 2026)
Genelux (GNLX) posted quarterly Shares Outstanding (Entity) of $44.8 million for Q1 2026, up 18.84% year-over-year from $37.7 million in Q1 2025, and up 17.57% quarter-over-quarter from $38.1 million in Q4 2025.
Genelux (GNLX) Shares Outstanding (2022 - 2026) Analysis & Trends
Genelux's Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $44.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 18.84% year-over-year to $44.8 million; the TTM figure through Mar 2026 stood at $44.8 million (up 18.84% YoY), while the FY2025 annual figure was $38.1 million, up 9.82% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $44.8 million, up from $38.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $44.8 million in Q1 2026, with the low at $9.1 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $30.8 million (2024), against an average of $28.3 million.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) surged 193.85% in 2023, then advanced 9.41% in 2025.
- Genelux's Shares Outstanding (Entity) stood at $9.1 million in 2022, then jumped by 193.85% to $26.8 million in 2023, then advanced by 29.64% to $34.7 million in 2024, then increased by 9.82% to $38.1 million in 2025, then grew by 17.57% to $44.8 million in 2026.
- Business Quant data shows GNLX's Shares Outstanding (Entity) at $44.8 million in Q1 2026, $38.1 million in Q4 2025, and $38.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | 44.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.15 Mn |
| Dec 31, 2025 | 37.18 Mn |
| Sep 30, 2025 | 37.89 Mn |
| Jun 30, 2025 | 37.95 Mn |
| Mar 31, 2025 | 34.93 Mn |
| Dec 31, 2024 | 31.45 Mn |
| Sep 30, 2024 | 34.53 Mn |
| Jun 30, 2024 | 29.69 Mn |
| Mar 31, 2024 | 26.85 Mn |
| Dec 31, 2023 | 24.43 Mn |
| Sep 30, 2023 | 26.21 Mn |
| Jun 30, 2023 | 25.07 Mn |
| Mar 31, 2023 | 19.58 Mn |
| Dec 31, 2022 | 9.12 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Mar 31, 2022 | 9.11 Mn |